What it's for (Indications)
- Macrogol, an osmotic laxative, is primarily indicated for the symptomatic treatment of chronic constipation in adults, adolescents, and children over specific age ranges depending on the formulation (e.
- g.
- , 2 years and above for certain pediatric preparations).
- It is also widely used for the resolution of faecal impaction, defined as refractory constipation with faecal loading of the rectum and/or colon, in adults and children.
- Its efficacy stems from its ability to soften hardened stools and facilitate bowel movements, thereby alleviating discomfort and promoting regular defecation.
- Prescribing decisions should always be made by a healthcare professional after a comprehensive assessment of the patient's condition, ruling out any underlying organic causes of constipation before initiating treatment.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For chronic constipation in adults and adolescents (over 12 years), the typical starting dose of macrogol is one sachet (e.g., containing 13.7g of macrogol 3350) taken one to three times daily, dissolved in approximately 125ml of water. The dose can be adjusted based on individual response, generally not exceeding three sachets daily. For fecal impaction, the recommended dosage regimen is considerably higher and administered over a short course, often for up to 3 days. For instance, adults may receive 8 sachets daily, dissolved in 1 litre of water and consumed within a 6-hour period. Pediatric dosing for both chronic constipation and fecal impaction is age- and weight-dependent and must be strictly guided by a healthcare professional to ensure safety and efficacy. It is crucial to maintain adequate fluid intake throughout treatment. The duration of treatment for chronic constipation typically does not exceed two weeks without medical review, although longer-term use may be acceptable under specialist supervision, particularly in chronic conditions where regular bowel evacuation is necessary. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects of macrogol are generally mild and transient, primarily affecting the gastrointestinal system.
- These include abdominal distension, abdominal pain, nausea, flatulence, and diarrhea.
- Diarrhea usually resolves with a reduction in dose.
- Less frequently, individuals may experience vomiting or anal discomfort.
- Rare but more serious adverse events can include allergic reactions, such as rash, urticaria, pruritus, dyspnoea, and in very rare cases, anaphylaxis or angioedema.
- Electrolyte disturbances, including hyponatremia and hypokalemia, are uncommon but can occur with prolonged high-dose use, particularly in vulnerable populations (e.
- g.
- , elderly, patients with renal impairment, or those on diuretics), necessitating careful monitoring in such instances.
- Patients should be advised to seek medical attention if any severe or persistent side effects occur.
Serious Warnings
- Black Box Warning: Macrogol does not carry a formal FDA Black Box Warning. However, serious warnings are associated with its use, particularly concerning patient safety. It is crucial to exclude organic disease and potential bowel obstruction before initiating treatment, as macrogol can exacerbate or mask underlying serious gastrointestinal conditions, including perforation. Patients experiencing unexplained severe abdominal pain, nausea, or vomiting should undergo a comprehensive medical evaluation prior to use. Prolonged or excessive use, especially without adequate fluid intake, may lead to significant electrolyte disturbances (e.g., hyponatremia, hypokalemia), particularly in elderly, renally impaired, or cardiac patients; monitoring of electrolytes may be necessary in such vulnerable populations. Rare but serious allergic reactions, including anaphylaxis, have been reported and require immediate medical attention. Caregivers should ensure proper dilution and administration to prevent esophageal irritation, particularly in pediatric patients or those with swallowing difficulties and impaired gag reflex.
- While macrogol is generally well-tolerated, several warnings and precautions must be observed.
- Patients should be adequately hydrated during treatment.
- The presence of symptoms suggestive of fluid or electrolyte imbalance should prompt immediate medical evaluation.
- Macrogol should be used with caution in patients with impaired gag reflex, prone to regurgitation or aspiration, or with significantly reduced levels of consciousness, as there is a potential risk of aspiration, particularly when administered in large volumes or improperly.
- Prolonged use without medical supervision is not recommended.
- If a patient develops diarrhea, particularly in the presence of existing electrolyte imbalance or dehydration, treatment should be temporarily discontinued, and electrolyte levels should be assessed.
- Patients with undiagnosed abdominal pain, nausea, or vomiting should not use macrogol without consulting a healthcare professional to rule out serious underlying conditions.
- Concurrent use with other medications may alter their absorption, so administration should be separated by at least 1-2 hours.
- Regular clinical assessment is essential to monitor response and safety, especially in pediatric and elderly populations.
How it Works (Mechanism of Action)
Macrogol (polyethylene glycol or PEG) functions as an osmotic laxative. It is a long-chain linear polymer that is highly water-soluble and virtually non-absorbed from the gastrointestinal tract. Upon oral administration, macrogol molecules pass through the gastrointestinal tract, retaining water through hydrogen bonding. This leads to an increase in the intraluminal volume of fluid in the bowel, which in turn softens the stool consistency and expands the colon content. The increased volume and softened stool stimulate peristalsis, promoting bowel motility and facilitating easier evacuation. The mechanism is purely physical, and macrogol is excreted unchanged in the faeces. This mode of action ensures minimal systemic absorption, contributing to its favorable safety profile compared to stimulant laxatives.
Commercial Brands (Alternatives)
No other brands found for this formula.